Tag: Parkinsonism

According to the National Institutes of Health, extrapyramidal symptoms (EPS) are a common side effect of antipsychotic medications, with prevalence estimates ranging significantly based on the specific drug used and patient population. This guide explains what are the four extrapyramidal symptoms, their characteristics, and how they relate to pharmacotherapy.

According to clinical trial data, parkinsonism—a movement disorder that includes rigidity—was reported in up to 25% of risperidone-treated adults with bipolar mania. This fact underscores why the question, **Does risperidone cause rigidity?**, is a crucial one for both patients and healthcare providers to address.

Estimates suggest that drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease. Understanding **which antipsychotics are lowest risk of parkinsonism** is a critical consideration in psychiatric pharmacology to mitigate this significant side effect. The risk varies considerably between medication types, with atypical antipsychotics generally offering a safer alternative to their first-generation counterparts.

Following reports of serious adverse reactions, particularly concerning neurological function, European regulatory agencies reviewed the safety of trimetazidine, highlighting significant long-term risks. These regulatory changes underscore the critical importance of understanding **what are the long-term side effects of trimetazidine** for patients and healthcare providers alike.

According to the European Medicines Agency (EMA), trimetazidine's use is restricted to certain angina patients due to concerns over its efficacy and safety. Before considering what happens if you stop taking trimetazidine, it is critical to understand the diverse outcomes depending on your underlying health condition and the reason for the medication's use.

A combination of haloperidol and trihexyphenidyl is a dual-action medication strategy used primarily for schizophrenia and other psychotic disorders. This combination pairs a potent antipsychotic with an anticholinergic agent to effectively manage psychiatric symptoms while mitigating the involuntary movement disorders associated with the primary drug.

First approved by the FDA in 1954, benztropine is a versatile anticholinergic medication primarily used to address movement-related issues in patients. A common question for those newly prescribed or researching the drug is: exactly what conditions does benztropine treat, and how effective is it for each?

Originally hailed for its ability to lower blood pressure, reserpine's dramatic impact on mental health and motor function led to a rapid decline in its use. But **what does reserpine do to the brain** at a neurochemical level to produce such profound effects, including sedation, depression, and parkinsonism? Its primary mechanism is the irreversible blocking of a key transporter for monoamine neurotransmitters.

Hyoscyamine has been used in clinical medicine for decades as an effective antispasmodic and antisecretory agent. The primary benefits of taking hyoscyamine are derived from its ability to relax the smooth muscles of the gastrointestinal (GI) and urinary tracts, providing significant relief for a range of conditions.

While true Parkinson's disease is a neurodegenerative disorder, drug-induced parkinsonism, a condition that mimics its symptoms, is known to be caused by certain medications. This raises a critical question for many users: Can Wellbutrin cause Parkinson's? The consensus is that while Wellbutrin does not cause the neurodegenerative disease itself, rare cases of reversible drug-induced parkinsonism have been reported.